Effect of Sustained-Release Morphine for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease on Health Status

RCT (n=124) reports regular, low-dose (10mg BD), oral sustained-release morphine for 4 weeks improved disease-specific health status (COPD Assessment Test) vs. placebo; score was 2.18 points lower in morphine group (95% CI, –4.14 to –0.22 points; p= 0.03), without affecting Paco2


JAMA Internal Medicine